BRAF and metastatic colorectal cancer: <h4>Background</h4>Dual blockade therapy encorafenib-cetuximab (EC) was recently established as the standard of care for second- or third-line treatment for <i>BRAF</i> <sup><i>V600E</i></sup> <i>-</i>mutated metastatic colorectal cancer (mCRC) patients based on BEACON phase III study results.